Skip to main content

Table 6 Percent inhibition of combined NRG/EGF/HGF cocktail signal with pan-HER inhibitors against each listed c-Met inhibitor on patient sample R66

From: Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

c-Met inhibitors

Average inhibition (%) w/different HER inhibitors

Capmatinib

94 (n = 6)

Savolitinib

98 (n = 6)

Tepotinib

96 (n = 6)

Cabozantinib

99 (n = 6)

Crizotinib

100 (n = 6)

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X